Race Oncology Ltd (ASX:RAC) has fielded “impressive” Phase 2 clinical trial results from its Acute Myeloid Leukaemia (AML) clinical trial. The interim clinical results are from an ongoing investigator-initiated Phase 2 trial of bisantrene in combination with fludarabine and clofarabine in…
Race Oncology Ltd (ASX:RAC) executive director Dr Pete Smith speaks with Proactive soon after announcing the company has initiated the toxicology and safety pharmacology studies required to support human clinical trials of its flagship bisantrene formulation for peripheral infusion, RC220. The company has…
Race Oncology Ltd (ASX:RAC) has welcomed preclinical findings on the anti-cancer efficacy of bisantrene, which demonstrate its potential in enhancing the cancer-killing activity of the widely used drug doxorubicin across a diverse range of 143 human cancer cell lines. Read more…
Writing in The Australian, Stockhead reported on Race Oncology’s revised corporate strategy. They spoke to Race Oncology CEO and MD Damian Clarke-Bruce about how Race Oncology is working to put itself at the heart of cancer care. Read the full…
Race Oncology CEO and MD Damian Clarke-Bruce and Chief Medical Officer Dr Michelle Rashford talked shareholders through Race’s refreshed corporate strategy and answered their questions during a webinar last week. Watch the full webinar here.
Proactive Investors reported on Race Oncology’s revised corporate strategy, designed to maximise the commercial potential of bisantrene. See the full report here.
Race Oncology Limited (“Race”) is pleased to provide shareholders with a strategic update, including an overview of revisions to corporate strategy, designed to optimise use of existing resources, while driving bisantrene’s commercial partnering and collaboration potential. Key highlights: Read the…
Proactive Investors reported on Race’s recent first half clinical programs update. Read the full story here.
Race Oncology is pleased to release a detailed commercial assessment of the market potential for Zantrene® as a cardio-protective agent or dual cardio-protective + anti-cancer in breast, endometrial and ovarian cancers.Key points from the research include: CEO and Managing Director,…
Race Oncology Limited (“Race”) announces Executive Director and Chief Scientific Officer (CSO), Dr Daniel Tillett has advised his decision to step down from his roles. Dr Tillett will provide ongoing support through June 2023 to ensure a smooth transition of…
